Chemotherapy With or Without Anti-EGFR Agents in Left- and Right-Sided Metastatic Colorectal Cancer: An Updated Meta-Analysis.

CONCLUSIONS: The addition of Cet/Pani to chemotherapy significantly benefits PFS and ORR in patients with RAS wt right-sided mCRC, indicating that anti-EGFR therapies may remain an option for selected patients. PMID: 31319395 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/31319395?dopt=Abstract

Source: Journal of the National Comprehensive Cancer Network : JNCCN - July 19, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research